keyword
https://read.qxmd.com/read/38520537/stereotactic-frame-based-biopsy-of-infratentorial-lesions-via-the-suboccipital-transcerebellar-approach-with-the-zamorano-duchovny-stereotactic-system-a-retrospective-analysis-of-79-consecutive-cases
#21
JOURNAL ARTICLE
Manuel Kaes, Christopher Beynon, Karl Kiening, Jan-Oliver Neumann, Martin Jakobs
OBJECTIVE: Lesions of the posterior fossa (brainstem and cerebellum) are challenging in diagnosis and treatment due to the fact that they are often located eloquently and total resection is rarely possible. Therefore, frame-based stereotactic biopsies are commonly used to asservate tissue for neuropathological diagnosis and further treatment determination. The aim of our study was to assess the safety and diagnostic success rate of frame-based stereotactic biopsies for lesions in the posterior fossa via the suboccipital-transcerebellar approach...
March 23, 2024: Acta Neurochirurgica
https://read.qxmd.com/read/38519329/recent-developments-in-convenience-of-administration-of-the-anti-cd38-antibody-isatuximab-subcutaneous-delivery-and-fast-intravenous-infusion-in-patients-with-multiple-myeloma
#22
REVIEW
Hang Quach, Gurdeep Parmar, Maria-Victoria Mateos, Sikander Ailawadhi, Xavier Leleu
Isatuximab-based combinations are among the accepted standard-of-care regimens for early-line treatment of patients with relapsed/refractory multiple myeloma (RRMM), based on the results of the Phase 3 ICARIA-MM and IKEMA trials. Further study findings have shown benefit with Isa-based combinations in patients with newly diagnosed MM, as reported from the randomized GMMG-HD7 and CONCEPT trials. Isa is currently approved in various countries for intravenous (IV) administration in patients with RRMM. A more convenient route of administration, such as subcutaneous (SC) injection, and faster IV infusion may substantially increase convenience of treatment...
February 12, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38517778/identification-of-a-prognostic-signature-based-on-five-ferroptosis-related-genes-for-diffuse-large-b-cell-lymphoma
#23
JOURNAL ARTICLE
Wuping Li, Ruizhe Yao, Nasha Yu, Weiming Zhang
BACKGROUND: Therapies for diffuse large B-cell lymphoma (DLBCL) are limited due to the diverse gene expression profiles and complicated immune microenvironments, making it an aggressive lymphoma. Beyond this, researches have shown that ferroptosis contributes to tumorigenesis, progression, and metastasis. We thus are interested to dissect the connection between ferroptosis and disease status of DLBCL. We aim at generating a valuable prognosis gene signature for predicting the status of patients of DLBCL, with focus on ferroptosis-related genes (FRGs)...
March 7, 2024: Cancer Biomarkers: Section A of Disease Markers
https://read.qxmd.com/read/38516380/il-2-cd25-axis-mediates-cellular-networks-promoting-the-growth-of-cd25-acute-myeloid-leukemia-cells
#24
JOURNAL ARTICLE
Kazunori Nakase, Kenkichi Kita
Although the expression of interleukin-2 receptor α-chain (IL-2Rα, CD25) has been provided prognostic significance independent of known biomarkers in acute myeloid leukemia (AML), the functional role of CD25 molecule remains unknown. Since IL-2 can be trans-presented via CD25 to another cell, CD25+ AML cells may deliver environmental IL-2 to surrounding immune cells to produce myeloid growth factors for their proliferation. We hypothesize that cellular interactions via IL-2/CD25 axis in the bone marrow microenvironment contributes to the growth advantage of these AML cells and affects the clinical outcome of those AML patients...
2024: Leukemia Research Reports
https://read.qxmd.com/read/38516299/car-designs-for-solid-tumors-overcoming-hurdles-and-paving-the-way-for-effective-immunotherapy
#25
JOURNAL ARTICLE
Yuanbin Cui, Mintao Luo, Chuanyuan Gu, Yuxian He, Yao Yao, Peng Li
Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized immunotherapy by modifying patients' immune cells genetically. By expressing CARs, these modified cells can specifically identify and eliminate tumor cells. The success of CAR-T therapy in hematological malignancies, such as leukemia and lymphoma, has been remarkable. Numerous studies have reported improved patient outcomes and increased survival rates. However, the application of CAR-T therapy in treating solid tumors faces significant challenges...
October 31, 2023: Biophysics Reports
https://read.qxmd.com/read/38515353/association-of-the-expression-of-th1-th2-cytokines-and-lymphocyte-subsets-with-clinical-characteristics-and-outcomes-in-207-chinese-children-with-burkitt-s-lymphoma
#26
JOURNAL ARTICLE
Shuang Huang, Ling Jin, Jing Yang, Yaguang Peng, Wenyu Gong, Shuo Hou, Tianyu Xing, Zhigang Li, Yanlong Duan
No abstract text is available yet for this article.
March 21, 2024: Chinese Medical Journal
https://read.qxmd.com/read/38515348/clinical-dose-rationale-of-tislelizumab-in-patients-with-solid-or-hematological-advanced-tumors
#27
JOURNAL ARTICLE
Tian Yu, Xiangyu Liu, Chi-Yuan Wu, Zhiyu Tang, Hongwei Wang, Patrick Schnell, Ya Wan, Kun Wang, Lucy Liu, Yuying Gao, Srikumar Sahasranaman, Nageshwar Budha
Tislelizumab, an anti-programmed cell death protein 1 monoclonal antibody, has demonstrated improved survival benefits over standard of care for multiple cancer indications. We present the clinical rationale and data supporting tislelizumab dose recommendation in patients with advanced tumors. The phase I, first-in-human, dose-finding BGB-A317-001 study (data cutoff [DCO]: August 2017) examined the following tislelizumab dosing regimens: 0.5-10 mg/kg every 2 weeks (q2w), 2-5 mg/kg q2w or q3w, and 200 mg q3w...
March 2024: Clinical and Translational Science
https://read.qxmd.com/read/38514025/fatal-outcome-of-bk-virus-encephalitis-in-an-allogeneic-stem-cell-transplantation-recipient
#28
Kyosuke Yamaguchi, Hisashi Yamamoto, Koji Izutsu, Mitsuhiro Yuasa, Daisuke Kaji, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Go Yamamoto, Yuki Asano-Mori, Naoyuki Uchida, Shuichi Taniguchi
BK virus (BKV) encephalitis is a rare complication after hematopoietic stem cell transplantation (HSCT). A 43-year-old woman with recurrent follicular lymphoma after autologous HSCT received allogeneic bone marrow transplantation from a human leukocyte antigen-matched related donor. Neutrophil engraftment was achieved on post-transplant day 13. Memory loss and noncooperative attitude toward the medical staff were observed on day 16, and her mental status worsened progressively. Magnetic resonance imaging (MRI) showed nonspecific findings on day 19; however, cerebrospinal fluid (CSF) analysis including real-time polymerase chain reaction on day 20 revealed elevated levels of BKV 4...
March 19, 2024: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy
https://read.qxmd.com/read/38513239/landscape-of-driver-mutations-and-their-clinical-effects-on-down-syndrome-related-myeloid-neoplasms
#29
JOURNAL ARTICLE
Tomohiko Sato, Kenichi Yoshida, Tsutomu Toki, Rika Kanezaki, Kiminori Terui, Ryunosuke Saiki, Masami Ojima, Yotaro Ochi, Seiya Mizuno, Masaharu Yoshihara, Tamayo Uechi, Naoya Kenmochi, Shiro Tanaka, Jun Matsubayashi, Kenta Kisai, Ko Kudo, Kentaro Yuzawa, Yuka Takahashi, Tatsuhiko Tanaka, Yohei Yamamoto, Akie Kobayashi, Takuya Kamio, Shinya Sasaki, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Hideki Muramatsu, Asahito Hama, Daisuke Hasegawa, Atsushi Sato, Katsuyoshi Koh, Shuhei Karakawa, Masao Kobayashi, Junichi Hara, Yuichi Taneyama, Chihaya Imai, Daiichiro Hasegawa, Naoto Fujita, Masahiro Yoshitomi, Shotaro Iwamoto, Genki Yamato, Satoshi Saida, Nobutaka Kiyokawa, Takao Deguchi, Masafumi Ito, Hidemasa Matsuo, Souichi Adachi, Yasuhide Hayashi, Takashi Taga, Akiko Moriya Saito, Keizo Horibe, Kenichiro Watanabe, Daisuke Tomizawa, Satoru Miyano, Satoru Takahashi, Seishi Ogawa, Etsuro Ito
Transient abnormal myelopoiesis (TAM) is a common complication in newborns with Down syndrome (DS). It commonly progresses to myeloid leukemia (ML-DS) after spontaneous regression. In contrast to the favorable prognosis of primary ML-DS, patients with refractory/relapsed ML-DS have poor outcomes. However, the molecular basis for refractoriness and relapse, and the full spectrum of driver mutations in ML-DS remain largely unknown. We conducted a genomic profiling study of 143 TAM, 204 ML-DS, and 34 non-DS acute megakaryoblastic leukemia cases, including 39 ML-DS cases analyzed by exome sequencing...
March 21, 2024: Blood
https://read.qxmd.com/read/38513161/cancer-treatment-disparities-in-people-with-hiv-in-the-united-states-2001-2019
#30
JOURNAL ARTICLE
Jennifer K McGee-Avila, Gita Suneja, Eric A Engels, Anne F Rositch, Marie-Josephe Horner, Qianlai Luo, Meredith S Shiels, Jessica Y Islam
PURPOSE: People with HIV (PWH) have worse cancer outcomes, partially because of inequities in cancer treatment. We evaluated cancer treatment disparities among PWH, including an assessment of changes in disparities over time. METHODS: We used data from the HIV/AIDS Cancer Match Study, a population-based HIV and cancer registry linkage to examine diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL), and cancers of the cervix, lung, anus, prostate, colon, and female breast...
March 21, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38512599/optimizing-real-world-outcomes-in-high-risk-relapsed-refractory-r-r-fl-with-car-t-cell-therapy-a-vodcast-and-case-example
#31
JOURNAL ARTICLE
Kai Hübel
Follicular lymphoma (FL) is often considered a chronic disease with frequent relapses, shortening both response duration and survival after every relapse. Selecting the most appropriate therapy at the right time within the treatment timeline is key to optimize outcomes. The aim of this vodcast, featuring Dr. Kai Hübel, is to outline the severity of FL by referring to a patient case as well as highlight chimeric antigen receptor (CAR)-T cells as an effective therapy in relapsed/refractory (r/r) FL. The patient was in their early 50s, diagnosed with FL in the early 2010s and presented with a third relapse...
March 21, 2024: Oncology and Therapy
https://read.qxmd.com/read/38512435/semi-supervised-learning-towards-automated-segmentation-of-pet-images-with-limited-annotations-application-to-lymphoma-patients
#32
JOURNAL ARTICLE
Fereshteh Yousefirizi, Isaac Shiri, Joo Hyun O, Ingrid Bloise, Patrick Martineau, Don Wilson, François Bénard, Laurie H Sehn, Kerry J Savage, Habib Zaidi, Carlos F Uribe, Arman Rahmim
Manual segmentation poses a time-consuming challenge for disease quantification, therapy evaluation, treatment planning, and outcome prediction. Convolutional neural networks (CNNs) hold promise in accurately identifying tumor locations and boundaries in PET scans. However, a major hurdle is the extensive amount of supervised and annotated data necessary for training. To overcome this limitation, this study explores semi-supervised approaches utilizing unlabeled data, specifically focusing on PET images of diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) obtained from two centers...
March 21, 2024: Physical and engineering sciences in medicine
https://read.qxmd.com/read/38510993/chimeric-antigen-receptor-t-cell-therapy-shows-similar-efficacy-and-toxicity-in-patients-with-diffuse-large-b-cell-lymphoma-aged-70-and-older-compared-to-younger-patients-a-multicenter-cohort-study
#33
JOURNAL ARTICLE
Philipp Berning, Evgenii Shumilov, Markus Maulhardt, Hristo Boyadzhiev, Andrea Kerkhoff, Simon Call, Christian Reicherts, Anna O Saidy, Enver Aydilek, Michèle Hoffmann, Urban Novak, Michael Daskalakis, Norbert Schmitz, Matthias Stelljes, Gerald Wulf, Ulrike Bacher, Georg Lenz, Thomas Pabst
CD19-directed chimeric antigen receptor (CAR)-T cell therapy has become a standard treatment for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). While the benefits of CAR-T cell treatment are clear in the general patient population, there remains a relative scarcity of real-world evidence regarding its efficacy and toxicity in patients (pts) aged ≥70 years with DLBCL. We conducted a multicenter retrospective analysis including 172 r/r DLBCL pts with CAR-T cell treatment, axicabtagene ciloleucel or tisagenlecleucel, between 2019 and 2023 at three tertiary centers...
March 2024: HemaSphere
https://read.qxmd.com/read/38510853/helicobacter-pylori-infection-and-complications-of-cirrhosis
#34
JOURNAL ARTICLE
Shefali Amin, Biraj Shrestha, Ameya Deshmukh, Manish Shrestha, Parth Desai, John Altomare
INTRODUCTION: Helicobacter pylori is a significant contributor to conditions such as peptic ulcer disease, gastric cancer, gastric mucosa-associated lymphoid tissue lymphoma, and colorectal cancer. Recent studies have suggested a potential link between H. pylori and cirrhosis. However, the impact of H. pylori on cirrhosis-related mortality, inpatient outcomes, and decompensating events remains unclear. Considering the widespread availability of H. pylori testing and effective treatment options, there is a potential rationale for eradicating H...
February 2024: Curēus
https://read.qxmd.com/read/38510818/refractory-burkitt-lymphoma-diagnosis-and-interventional-strategies
#35
REVIEW
Francesco Malfona, Anna Maria Testi, Sabina Chiaretti, Maria Luisa Moleti
Despite excellent results in frontline therapy, particularly in pediatric age, refractory Burkitt lymphoma still remains a therapeutic challenge, with dismal outcome. The prognosis is very poor, ranging from less than 10% to 30-40%, with longer survival only in transplanted patients. On account of the paucity of data, mostly reporting on small series of patients, with heterogeneous characteristics and salvage treatments, at present it is impossible to draw definitive conclusions on the treatment of choice for this difficult to treat subset of patients...
2024: Blood and Lymphatic Cancer: Targets and Therapy
https://read.qxmd.com/read/38509603/the-potential-value-of-ultrasound-in-predicting-local-refractory-relapse-events-in-primary-thyroid-lymphoma-patients
#36
JOURNAL ARTICLE
Jiang Ji, Luying Gao, Ruifeng Liu, Xinlong Shi, Liyuan Ma, Aonan Pan, Naishi Li, Chunhao Liu, Xiaoyi Li, Meng Yang, Yu Xia, Yuxin Jiang
BACKGROUND: Primary thyroid lymphoma (PTL) is a rare malignant disorder, and ultrasound plays an important role in PTL diagnosis and follow-up surveillance. Prediction of refractory/relapse events in PTL patients is an essential issue, yet no ultrasonic PTL features have been discovered to be related to refractory/local relapse events. METHODS: From January 2008 to September 2022, newly diagnosed PTL patients in our center who underwent standard first-line treatment and received an ultrasound examination before treatment were enrolled...
March 20, 2024: Cancer Imaging: the Official Publication of the International Cancer Imaging Society
https://read.qxmd.com/read/38509433/clinical-management-of-patients-with-non-small-cell-lung-cancer-brain-metastases-and-actionable-genomic-alterations-a-systematic-literature-review
#37
REVIEW
Mustafa Khasraw, Priyanka Yalamanchili, Anu Santhanagopal, Chuntao Wu, Maribel Salas, Jie Meng, Maha Karnoub, Stephen Esker, Enriqueta Felip
INTRODUCTION: Nearly 60% of patients with non-small cell lung cancer (NSCLC) present with metastatic disease, and approximately 20% have brain metastases (BrMs) at diagnosis. During the disease course, 25-50% of patients will develop BrMs. Despite available treatments, survival rates for patients with NSCLC and BrMs remain low, and their overall prognosis is poor. Even with newer agents for NSCLC, options for treating BrMs can be limited by their ineffective transport across the blood-brain barrier (BBB) and the unique brain tumor microenvironment...
March 21, 2024: Advances in Therapy
https://read.qxmd.com/read/38508620/rituximab-combined-anthracycline-free-chemotherapy-in-newly-diagnosed-paediatric-and-adolescent-patients-with-non-high-risk-aggressive-mature-b-cell-lymphoma-protocol-for-a-single-arm-open-label-multicentre-phase-ii-study-the-japan-children-s-cancer-group-multicentre
#38
JOURNAL ARTICLE
Masahiro Sekimizu, Reiji Fukano, Yuhki Koga, Tetsuo Mitsui, Naoto Fujita, Takeshi Mori, Daiki Hori, Makito Tanaka, Kentaro Ohki, Hideto Iwafuchi, Atsuko Nakazawa, Tetsuya Mori, Ryoji Kobayashi, Hiroya Hashimoto, Akiko M Saito, Michi Kamei
INTRODUCTION: Children and adolescents with mature B cell non-Hodgkin lymphoma (B-NHL) are treated with short-intensive chemotherapy. The burden of short-term and long-term toxicity is highly relative to its high cure rate in good-risk patients. Although the addition of rituximab to standard lymphome Malin B (LMB) chemotherapy markedly prolongs event-free survival and overall survival in high-risk patients, the benefit of rituximab in good-risk patients remains to be elucidated. This clinical trial will examine whether the addition of rituximab eliminates anthracyclines in good-risk patients without compromising treatment outcomes...
March 19, 2024: BMJ Open
https://read.qxmd.com/read/38507740/inhibition-of-malt1-and-bcl2-induces-synergistic-anti-tumor-activity-in-models-of-b-cell-lymphoma
#39
JOURNAL ARTICLE
Joshua P Plotnik, Adam E Richardson, Haopeng Yang, Estela Rojas, Velitchka Bontcheva, Colleen Dowell, Sydney Parsons, Ashley Wilson, Vida Ravanmehr, Christine Will, Paul Jung, Haizhong Zhu, Sarathy Karunan Partha, Sanjay C Panchal, Raghuveer Singh Mali, Frederick J Kohlhapp, Ryan A McClure, Cyril Y Ramathal, Mariam D George, Manisha Jhala, Nathaniel L Elsen, Wei Qiu, Russell A Judge, Chin Pan, Anthony Mastracchio, Jared Henderson, Jonathan A Meulbroek, Michael R Green, William N Pappano
The activated B cell (ABC) subset of diffuse large B cell lymphoma (DLBCL) is characterized by chronic B cell receptor signaling and associated with poor outcomes when treated with standard therapy. In ABC-DLBCL, MALT1 is a core enzyme that is constitutively activated by stimulation of the B cell receptor or gain-of-function mutations in upstream components of the signaling pathway, making it an attractive therapeutic target. We discovered a novel small molecule inhibitor, ABBV-MALT1, that potently shuts down B cell signaling selectively in ABC-DLBCL preclinical models leading to potent cell growth and xenograft inhibition...
March 20, 2024: Molecular Cancer Therapeutics
https://read.qxmd.com/read/38506231/treatment-outcome-toxicity-and-quality-of-life-of-patients-with-bronchus-associated-lymphoid-tissue-lymphoma
#40
JOURNAL ARTICLE
Lin-Rui Gao, Xinyue Wang, Yunpeng Wu, Xiao-Li Feng, Wei Rao, Xin Liu, Yong-Wen Song, Hui Fang, Bo Chen, Jing Jin, Yue-Ping Liu, Hao Jing, Yuan Tang, Ning-Ning Lu, Ning Li, Wen-Wen Zhang, Yirui Zhai, Shu-Lian Wang, Shu-Nan Qi, Ye-Xiong Li
The disease failure patterns and optimal treatment of bronchus-associated lymphoid tissue (BALT) lymphoma are unknown. This retrospective study involved 71 patients with primary BALT lymphoma who had received radiotherapy (RT), surgery, immunochemotherapy (IC), or observation. The median follow-up time was 66 months. The 5-year overall survival and lymphoma-specific survival were 91.2% and 96.1%, respectively, and were not significantly different among treatments. The 5-year cumulative incidence of overall failure for RT, surgery, IC, and observation was 0%, 9...
March 20, 2024: Leukemia & Lymphoma
keyword
keyword
162410
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.